Current
22.1×
5-Year Average
17.6×
All-Time High
56.7×
All-Time Low
8.8×
P/FCF Ratio daily chart for Amgen (AMGN)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/FCF Ratio for Amgen (AMGN) from 2001 to 2025
| 2025 | $176.42B | $8.10B | 21.8× | +8.2× | |
| 2024 | $140.88B | $10.39B | 13.6× | -7.4× | |
| 2023 | $154.09B | $7.36B | 20.9× | +4.9× | |
| 2022 | $140.51B | $8.79B | 16.0× | +0.9× | |
| 2021 | $126.43B | $8.38B | 15.1× | +1.6× | |
| 2020 | $133.58B | $9.89B | 13.5× | -3.2× | |
| 2019 | $142.95B | $8.53B | 16.8× | +5.0× | |
| 2018 | $123.62B | $10.56B | 11.7× | -0.3× | |
| 2017 | $125.83B | $10.51B | 12.0× | +0.6× | |
| 2016 | $108.49B | $9.52B | 11.4× | -3.1× | |
| 2015 | $122.40B | $8.43B | 14.5× | -1.5× | |
| 2014 | $121.22B | $7.55B | 16.1× | +0.7× | |
| 2013 | $86.02B | $5.60B | 15.4× | +2.7× | |
| 2012 | $65.77B | $5.19B | 12.7× | +1.5× | |
| 2011 | $50.79B | $4.55B | 11.2× | +1.3× | |
| 2010 | $51.22B | $5.21B | 9.8× | +0.3× | |
| 2009 | $55.55B | $5.81B | 9.6× | -1.6× | |
| 2008 | $59.60B | $5.32B | 11.2× | -1.0× | |
| 2007 | $50.57B | $4.13B | 12.2× | -6.9× | |
| 2006 | $79.72B | $4.17B | 19.1× | -4.3× | |
| 2005 | $94.79B | $4.04B | 23.4× | -10.5× | |
| 2004 | $80.12B | $2.36B | 33.9× | -1.8× | |
| 2003 | $79.05B | $2.21B | 35.8× | -3.5× | |
| 2002 | $62.38B | $1.59B | 39.2× | -17.5× | |
| 2001 | $58.90B | $1.04B | 56.7× | — |
- 202521.8×
- 202413.6×
- 202320.9×
- 202216.0×
- 202115.1×
- 202013.5×
- 201916.8×
- 201811.7×
- 201712.0×
- 201611.4×
- 201514.5×
- 201416.1×
- 201315.4×
- 201212.7×
- 201111.2×
- 20109.8×
- 20099.6×
- 200811.2×
- 200712.2×
- 200619.1×
- 200523.4×
- 200433.9×
- 200335.8×
- 200239.2×
- 200156.7×
About P/FCF Ratio at Amgen (AMGN)
Amgen (AMGN) P/FCF ratio is 22.1× as of June 5, 2026. The 5-year average is 17.6×. The sector median currently stands at 19.8×. The current ratio is at the 80th percentile of its own 10-year history.
Amgen (AMGN) historical P/FCF ratio has ranged from a low of 8.8× (2010) to a high of 56.7× (2001) in the available daily series.
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Amgen P/FCF Ratio by Year
Amgen P/FCF Ratio 2025: 21.8×
Amgen (AMGN) P/FCF ratio in 2025 was 21.8×, expanded from 13.6× the prior year.
Amgen P/FCF Ratio 2024: 13.6×
Amgen (AMGN) P/FCF ratio in 2024 was 13.6×, contracted from 20.9× the prior year.
Amgen P/FCF Ratio 2023: 20.9×
Amgen (AMGN) P/FCF ratio in 2023 was 20.9×, expanded from 16.0× the prior year.
Amgen P/FCF Ratio 2022: 16.0×
Amgen (AMGN) P/FCF ratio in 2022 was 16.0×, expanded from 15.1× the prior year.
Amgen P/FCF Ratio 2021: 15.1×
Amgen (AMGN) P/FCF ratio in 2021 was 15.1×.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of Amgen (AMGN), ranked by P/FCF ratio.
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
Amgen (AMGN) Key Financials
Charts, filings, and peer comparison for every metric